ClinicalTrials.gg
Active, not recruitingNCT03769506Updated Jan 16, 2025

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

A Phase 3 interventional study of ASP-1929 Photoimmunotherapy and Physician's Choice SOC in Head and Neck Cancer, sponsored by Rakuten Medical, Inc.. Active, not recruiting at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's title name Squamous Cell Carcinoma of Head and Neck, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Rakuten Medical, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India — 12 open to participants now, 14 under way, 7 of them phase 3. Squamous Cell Carcinoma of Head and Neck · India.

Enrollment
19th of 31
135 · median 224
Started
2019
with 1 other
Phase 3
12 of 33
4 open now
Primary completion
2025-12
later than 0 of 13 live
Registered
18th of 33
by date

Among the 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2019, is one of 12 in phase 3, reaches primary completion later than 0 of the 13 other live ones, and was the 18th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

12 of the 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India, or all of them as a file.
02

Study summary

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy

Read the detailed description

The study will have an Experimental Arm and a Control Arm.

Experimental Arm:

Patients may receive repeated ASP-1929 PIT interventions for up to a maximum of 8 cycles within a period of up to 12 months after randomization until the patient has complete remission, progressive disease that is no longer amendable to study treatment, patient experiences intolerable side effects, patient discontinues study treatment, or chooses to withdraw. Repeat ASP-1929 treatment cycles will be administered no less than 4 weeks from the previous ASP-1929 infusion.

Control Arm:

Patients may be treated with physician's choice standard of care until the patient has progressive disease, patient experiences intolerable side effects, discontinues study treatment, or chooses to withdraw.

03

Conditions studied

  • Head and Neck Cancer

Browse trials for

Keywords

  • Rakuten Medical
  • ASP-1929
  • PIT
  • Photoimmunotherapy
  • HNC
  • HNSCC
  • Head and neck
  • EGFR
  • Cetuximab
  • Erbitux
  • RM-1929
04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's enrollment of 135 is above the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

Rakuten Medical, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Overall Inclusion Criteria:

  • Have a confirmed locoregional persistent, recurrent or second primary squamous cell carcinoma of the head and neck, not amenable to curative treatment
  • Have failed or progressed on or after at least 2 for squamous cell carcinoma of the head and neck, one of which must be prior systemic platinum-based chemotherapy
  • Have completed prior curative radiation therapy for treatment of their head and neck region
  • Have locoregional head and neck tumor site(s) that are all accessible to light illumination
  • Have target tumors that are clearly measurable by contrast enhanced CT scan, or MRI scan with gadolinium if CT scan is not adequate or the patient has an allergy to CT contrast media.
  • Have a of > 6 months, based on Investigator judgment
  • Male participants must agree to use during the treatment period and for at least 6 months after the last ASP-1929 infusion
  • Female patients of must not be pregnant or breastfeeding and agree to follow the contraceptive guidance during the treatment period and for at least 6 months after the last dose of trial intervention and must refrain from breastfeeding for at least 2 months after the last ASP-1929 infusion
  • Have an (ECOG) score of 0 or 1

Overall Exclusion Criteria:

  • Have a history of significant (>= Grade 3) cetuximab infusion reactions
  • Have been treated with prior systematic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of trial Day 1 or not recovered from adverse events due to a previously administered agent
  • Have been treated with an anticancer monoclonal antibody therapy within 4 weeks of trial Day 1 or have not recovered from adverse events due to previously administered agent
  • Have been treated with an agent or intervention within 4 weeks of trial Day 1 or have not recovered from adverse events, due to previously administered agent or intervention
  • Have a present history of distant disease (M1)
  • Have an active undergoing treatment or have a diagnosis of an active cancer other than nonmelanoma skin cancer or HNSCC
  • Have a tumor in enhanced CT or MRI scan invading a major blood vessel, unless the vessel has been embolized, stented or surgically ligated to prevent potential bleeding from a blood vessel
  • Have impaired hepatic function
  • Have impaired renal function
  • Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with trial requirements
  • Have been previously treated or randomized to any trial using ASP-1929 or RM-1929 PIT as the study treatment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    ASP-1929 Photoimmunotherapy

    Use of ASP-1929 Photoimmunotherapy

    Combination Product: ASP-1929 Photoimmunotherapy

  • Active comparator
    Physician's Choice SOC

    docetaxel, cetuximab, methotrexate, paclitaxel

    Drug: Physician's Choice SOC

Interventions

07

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS, defined as the time from randomization to the first occurrence of disease progression (PD), as determined by the Central Radiographic Review according to RECIST 1.1 with modifications, or death from any cause, whichever occurs first.

    Time frame: 24 months

  2. Overall Survival (OS)

    OS, defined by the time interval between the patient randomization and death due to any cause.

    Time frame: 24 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR, defined by the percentage of patients with the best overall response of complete response (CR) or partial response (PR) by RECIST 1.1 with modifications.

    Time frame: 24 months

  2. Duration of Response (DoR)

    DoR, defined as the time from first objective response (CR or PR) to the date of the first documented tumor progression, as determined by Central Radiographic Review according to RECIST 1.1 criteria with modifications or date of death due to any cause, whichever occurs first.

    Time frame: 24 months

  3. Event-Free Survival (EFS)

    EFS, defined as the time interval from randomization to a \>20% increase in tumor size from baseline (CT or MRI scan at screening) by Central Radiographic Review according to RECIST 1.1 with modifications, development of new locoregional disease, distant metastatic disease, or death, whichever occurs first.

    Time frame: 24 months

  4. Eastern Cooperative Oncology Group (ECOG) performance status

    Time frame: 24 months

  5. Quality of Life (QoL) assessment - EORTC QLQ-C30

    Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). EORTC QLQ-C30 is a 30-item questionnaire developed to assess QoL of head and neck cancer participants and consists of five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease. It has four-point scales for the first 28 items. The minimum value is 1 and maximum value is 4. Higher scores mean a worse outcome. Overall health was evaluated as a 7-point response scale as the other two questions in that scale. The minimum value is 1 and maximum value is 7. Higher scores mean a better outcome.

    Time frame: 24 months

  6. Quality of Life (QoL) assessment - EORTC QLQ H&N 35

    Change from baseline in EORTC head and neck specific module (EORTC QLQ H\&N 35). EORTC QLQ-H\&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multiple-item scales that assess the symptom of pain, swallowing, senses (taste/smell), speech, social eating, social contact and sexuality. Also, six single-item scales are included to survey the presence of symptomatic problems associated with teeth, mouth=opening, dry mouth, sticky saliva, coughing, and feeling ill. The minimum value is 1 and maximum value is 4. It has 2-point scales for the last 5 items. The minimum value is 1 and maximum value is 2. For all items and scales, high scores indicate more problems.

    Time frame: 24 months

  7. Quality of Life (QoL) assessment - EQ 5D-5L

    Change from baseline in EuroQol 5-Dimension 5-Level (EQ 5D-5L) Questionnaire. EQ-5D-5L is a 5-dimension (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) questionnaire developed to assess the patient-generated health state index score from the societal perspective and subjective perceived health. For each dimension, levels of perceived problems are coded from level 1 (minimum) to level 5 (maximum): no problems (1), slight problems (2), moderate problems (3), severe problems (4), and extreme problems/inability (5). A second part of the questionnaire provides a visual analogue scale (VAS) for individually perceived health from 0 to 100 (corresponding to the worst to the best imaginable health).

    Time frame: 24 months

  8. Population Pharmacokinetics (PK) of ASP-1929

    Estimate covariate effects of ASP-1929 PK through compartmental PK modeling.

    Time frame: 12 months

  9. Presence of Anti-Drug Antibodies (ADA) of ASP-1929

    Time frame: 24 months

  10. Complete Response (CR)

    CR, defined as the proportion of patients with tumor response of CR, as determined by Central Radiographic Review according to RECIST 1.1 with modifications.

    Time frame: 24 months

  11. Complete Response by Biopsy (CRb)

    CR by histopathologic biopsy of target tumor(s) and a repeated confirmatory histopathologic CR biopsy at least 3 months after initial CR histopathologic biopsy of the target tumor(s) for patients who demonstrate a clinical CR but not an image CR per RECIST 1.1 with modifications, as determined by the Investigator.

    Time frame: 24 months

08

Study locations

22 sites
  • Cancer Clinic
    Miami, Florida 33176, United States
  • Cancer Clinic
    Tampa, Florida 33606, United States
  • Cancer Clinic
    Atlanta, Georgia 30322, United States
  • Cancer Clinic
    Lexington, Kentucky 40536, United States
  • Cancer Clinic 1
    Philadelphia, Pennsylvania 19107, United States
  • Cancer Clinic 2
    Philadelphia, Pennsylvania 19107, United States
  • Cancer Clinic
    Houston, Texas 77030, United States
  • Cancer Clinic
    Vadodara, Gujarat 390011, India
  • Cancer Clinic
    Vadodara, Gujarat 391760, India
  • Cancer Clinic
    Bangalore, Kamataka 560099, India
  • Cancer Clinic
    Kochi, Kerala 682041, India
  • Cancer Clinic
    Chennai, Tamilnadu 600036, India
  • Cancer Clinic
    Hyderabad, Telangana 500034, India
  • Cancer Clinic
    Kolkata, West Bengal 700160, India
  • Cancer Clinic
    Mumbai, 400012, India
  • Cancer Clinic
    Nagoya-shi, Aichi 464-8681, Japan
  • Cancer Clinic
    Sapporo-shi, Hokkaido 060-8648, Japan
  • Cancer Clinic
    Okayama-shi, Okayama 700-8558, Japan
  • Cancer Clinic
    Chuo-ku, Tokyo 104-0045, Japan
  • Cancer Clinic
    Taichung, 40705, Taiwan
  • Cancer Clinic
    Taipei, 10048, Taiwan
  • Cancer Clinic
    Taoyuan, 33305, Taiwan
09

References and documents

Publications

  • Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int Immunol. 2021 Jan 1;33(1):7-15. doi: 10.1093/intimm/dxaa037. PubMed 32496557 ↗
  • Kobayashi H, Choyke PL. Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res. 2019 Aug 20;52(8):2332-2339. doi: 10.1021/acs.accounts.9b00273. Epub 2019 Jul 23. PubMed 31335117 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Dec 2025, 79 months after the start.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's planned 79 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2018
First posted
Dec 7, 2018
StartActual
May 9, 2019
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03769506
Lead sponsor
Rakuten Medical, Inc.
Responsible party
Sponsor
First posted
Dec 7, 2018
Start date
May 9, 2019
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 16, 2025

Study contacts

Ethan Chen, MD
study director · Rakuten Medical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab sarotalocan sodium

Start the discussion